Overview: Atypical ANCA Titer TestIntroduction: The Atypical ANCA Titer Test measures the level of atypical ANCA antibodies to assess the severity of vasculitis, helping doctors manage this condition causing blood vessel inflammation and organ issues. Affecting 1 in 10,000 people annually, vasculitis poses management challenges due to its progressive nature. Following 2023 American College of Rheumatology (ACR) guidelines, it uses immunofluorescence for high specificity, supporting immunology screening. This test is crucial for monitoring, treatment adjustment, and improving outcomes in rheumatology.
Other Names: Atypical ANCA Titer Assay, Atypical Vasculitis Titer Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic reliability.
Historical Milestone: ANCA titer testing evolved in the 1990s with research by Gross, who refined atypical ANCA detection. Immunofluorescence advancements in the 2000s by Inova Diagnostics enhanced precision, surpassing earlier manual methods.
Purpose: Measures atypical ANCA titer to assess vasculitis severity, guides therapy adjustments with steroids or immunosuppressants, and monitors patients with organ dysfunction, aiming to prevent complications.
Test Parameters: Atypical ANCA titer
Pretest Condition: No special preparation required to reflect natural antibody levels. Collect serum. Report history of organ issues.
Specimen: Serum (SST, 2-5 mL); 2 mL serum in SST. Transport in a biohazard container to prevent degradation.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document fatigue, fever, or organ dysfunction. Include current medications or treatment history.
Consent: Written consent required, detailing the test's purpose, vasculitis risks (e.g., kidney failure), and sample collection risks.
Procedural Considerations: Uses immunofluorescence to measure atypical ANCA titer, requiring labs with fluorescent microscopes. Results available in 3-5 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample hemolysis or contamination can affect results. Medications may alter levels, requiring correlation.
Clinical Significance: High titer indicates severe vasculitis, guiding intensified therapy. Monitoring helps prevent organ damage, while uncontrolled cases lead to death. Normal levels may suggest remission.
Specialist Consultation: Consult a rheumatologist for interpretation.
Additional Supporting Tests: c-ANCA, p-ANCA, or imaging to assess disease activity.
Test Limitations: Non-specific for severity; correlation with symptoms needed. Variability in antibody levels may occur.
References: ACR Guidelines, 2023; Journal of Rheumatology, Gross WL, 2022.
